Track Norris Medicines Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -14.74 %
Low
15.5
High
18.9
1 Month returns: 18.61 %
Low
13.5
High
20.1
1 Year returns: 0.12 %
Low
12.0
High
20.1
3 Year CAGR: 12.08 %
Low
10.6
High
27.7
5 Year CAGR: 9.15 %
Low
8.1
High
36.8
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Norris Medicines Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Norris Medicines Ltd. Shareholding Pattern
Quarterly breakdown of Norris Medicines Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Norris Medicines Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Norris Medicines Ltd.?
The current share price of Norris Medicines Ltd. is ₹ 16.19 as of 5 Oct 2026.
What is the market capitalisation of Norris Medicines Ltd.?
The market capitalisation of Norris Medicines Ltd. stands at ₹ 16.19 Cr.
What is the PE ratio of Norris Medicines Ltd.?
The Price-to-Earnings (PE) ratio of Norris Medicines Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Norris Medicines Ltd.?
Norris Medicines Ltd. has a Return on Equity (ROE) of - and a Return on Capital Employed (ROCE) of 2.66% as per the latest financial reports.
What is the 52-week high and low of Norris Medicines Ltd.?
The 52-week high of Norris Medicines Ltd. is - and the 52-week low is -.
What is the dividend yield of Norris Medicines Ltd.?
The dividend yield of Norris Medicines Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Norris Medicines Ltd.?
Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.07% and retail/public investors hold 22.01% of Norris Medicines Ltd. shares.
What sector does Norris Medicines Ltd. belong to?
Norris Medicines Ltd. operates in the Services sector.
What is the beta of Norris Medicines Ltd.?
The beta of Norris Medicines Ltd. is 0.27, indicating its price volatility relative to the broader market. Over the past 1 year, Norris Medicines Ltd. has delivered an absolute return of 1.06%.
What is the RSI of Norris Medicines Ltd.?
The 14-day Relative Strength Index (RSI) of Norris Medicines Ltd. is 45.09, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Norris Medicines Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Moderate revenue growth and above median growth of industry
The company delivered moderate revenue growth of 16.0% for 12-month ended 30 Jun 2026 and the growth was 16.14 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: -0.14
Value 16
-127.35379742
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 68.46% for 12-month ended 30 Jun 2026 and the growth was 82.26 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of -2.27% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Low operating margin but improving trend
The company reported low operating margin of -0.0% for 12-month ended 30 Jun 2026 but operating margin improved by 1113 bps from 1 year ago
What is Operating profit margin?
Thinly traded (low daily turnover)
The stock is thinly traded with combined (NSE & BSE) daily turnover (21-day average) of 0.00278917.
Net Revenue FY
Profit After Tax FY
ROE FY
Not enough data
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
10.44
10.44
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.01
34.01
34.01
34.01
34.01
34.01
34.00
34.00
34.00
34.00
34.00
34.01
34.01
Indian Promoter
10.44
10.44
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.04
34.01
34.01
34.01
34.01
34.01
34.01
34.00
34.00
34.00
34.00
34.00
34.01
34.01
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.07
Mutual Funds / UTI
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
FI/Bank/Insurance
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.06
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Institutions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non-Institution
89.49
89.49
65.89
65.89
65.89
65.89
65.89
65.89
65.89
65.89
65.89
65.89
65.89
65.92
65.92
65.92
65.92
65.92
65.92
65.93
65.93
65.93
65.93
65.93
65.92
65.92
Bodies Corporate
43.99
43.99
43.99
43.99
43.99
43.99
44.00
44.03
44.00
44.00
43.98
43.98
43.98
43.98
43.96
43.96
43.94
43.94
43.94
43.94
43.94
43.92
43.92
43.91
43.91
43.91
Others (incl. Retail)
No. of shareholders
45.50
25,111
45.50
25,092
21.90
25,046
21.90
24,986
21.90
24,930
21.90
24,952
21.89
24,938
21.86
25,060
21.89
25,211
21.89
25,215
21.91
25,252
21.91
25,310
21.91
25,252
21.94
25,182
21.96
25,167
21.96
25,244
21.98
25,445
21.98
25,328
21.98
25,425
21.99
25,587
21.99
25,743
22.01
25,880
22.01
25,825
22.02
25,722
22.01
25,708
22.01
25,708
Corporate Actions
History of Norris Medicines Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Others
Ex-date: 22nd Aug 2013Announced on: 20th Aug 2013
The existing paid up capital has been reduced by 70 percent as a result every 10 equity shares has been consolidated into 3 equity shares.
Company Profile
Overview of Norris Medicines Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Norris Medicines Limited is an India-based company, which is focused on the health care industry. The Company is engaged in the manufacturing and exporting medicines and injections. The Company’s product categories include antibiotic, anti-inflammatory and analgesic range, G. I. range, dermatological range, nutrition range, anti-malaria, anti-emetic, cough/cold range, dental range, diabetics and cardiac, and miscellaneous range. Its antibiotic products include Arizon-100, Arizon-250, Arizon-500, Cefan-dry syurp, and Cefan DT-50. Its G.I. products include Denzym Syrup, Denzym Oral Drop, Ezynor-20, Regus-DSR, Sucrinor and Rinotac. Its dermatological products include Clobec-G, Gabax, Morfit Plus, Novadin-M, Silwon-C and Tioderm. Its nutrition products include Cand XP, Cand Fort, Can D suspension and Hemfit Plus Syrup. It has two plants situated at GIDC, Ankleshwar, Gujarat. Both the plants of the Company are World Health Organization Good Manufacturing Practices (WHO GMP) approved.
Norris Medicines Limited is an India-based company, which is focused on the health care industry. The Company is engaged in the manufacturing and exporting medicines and injections. The Company’s product categories include antibiotic, anti-inflammatory and analgesic range, G. I. range, dermatologica...